South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Shares of Eli Lilly (NYSE: LLY) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker with a market cap of over $500 billion is in a sharp drawdown due to ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount of weight, the company said.

Eli Lilly stock hasn't been performing this badly since the Great Recession Prior to Thursday's sell-off, the stock was on track for its worst year since 2016.

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, while the Nasdaq eked out a record closing high.

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on genetics and financial implications.

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down By Ty Roush, Forbes Staff. Ty Roush is a breaking news reporter based in New York City.

Shares of Eli Lilly(NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for the second quarter of 2025 that beat expectations, with soaring sales of ...